1Srivastava S, Lundqvist A, Childs RW. Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy 2008; 10: 775–783.
2Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5: 112–117.
3Gillgrass A, Ashkar A. Stimulating natural killer cells to protect against cancer: recent developments. Expert Rev Clin Immunol 2011; 7: 367–382.
4Vivier E, Colonna M. (Eds.). Immunobiology of Natural Killer Cell Receptors. Springer-Verlag Berlin Heidelberg, 2006, Vol. VIII, p. 284.
5Di Santo JP. Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006; 24: 257–286.
6Puzanov IJ, Bennett M, Kumar V. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J Immunol 1996; 157: 4282–4285.
7Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007; 7: 703–714.
8Chiossone L et al. Maturation of mouse NK cells is a 4-stage developmental program. Blood 2009; 113: 5488–5496.
9Fu B et al. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology 2011; 133: 350–359.
10Kim S et al. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A 2000; 97: 2731–2736.
